Basilea Pharmaceutica (BPMUF)
(Delayed Data from OTC)
$47.00 USD
0.00 (0.00%)
Updated Jul 17, 2024 02:00 PM ET
3-Hold of 5 3
B Value D Growth D Momentum D VGM
Brokerage Reports
Basilea Pharmaceutica AG [BPMUF]
Reports for Purchase
Showing records 21 - 40 ( 73 total )
Company: Basilea Pharmaceutica AG
Industry: Medical - Biomedical and Genetics
Zevtera (ceftobiprole) clinical data published
Provider: Edison Investment Research Limited
Analyst: ROMANOFF S
Company: Basilea Pharmaceutica AG
Industry: Medical - Biomedical and Genetics
A strong start to FY23 across the board
Provider: Edison Investment Research Limited
Analyst: ROMANOFF S
Company: Basilea Pharmaceutica AG
Industry: Medical - Biomedical and Genetics
Mid-Year Report Showcases Impressive Operating Progress; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Basilea Pharmaceutica AG
Industry: Medical - Biomedical and Genetics
Cresemba Supplemental New Drug Application Accepted; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Basilea Pharmaceutica AG
Industry: Medical - Biomedical and Genetics
Zevtera back on track: NDA submitted to the FDA
Provider: Edison Investment Research Limited
Analyst: ROMANOFF S
Company: Basilea Pharmaceutica AG
Industry: Medical - Biomedical and Genetics
Ceftobiprole New Drug Application Submitted to FDA; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Basilea Pharmaceutica AG
Industry: Medical - Biomedical and Genetics
Ceftobiprole Regulatory Submission Imminent; Raising PT to CHF90
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Basilea Pharmaceutica AG
Industry: Medical - Biomedical and Genetics
Prompt receipt of milestone payments for Cresemba
Provider: Edison Investment Research Limited
Analyst: ROMANOFF S
Company: Basilea Pharmaceutica AG
Industry: Medical - Biomedical and Genetics
Zevtera NDA submission pushed to Q323
Provider: Edison Investment Research Limited
Analyst: ROMANOFF S
Company: Basilea Pharmaceutica AG
Industry: Medical - Biomedical and Genetics
Cresemba expansion continues with Japan launch
Provider: Edison Investment Research Limited
Analyst: ROMANOFF S
Company: Basilea Pharmaceutica AG
Industry: Medical - Biomedical and Genetics
Company: Basilea Pharmaceutica AG
Industry: Medical - Biomedical and Genetics
Strong execution resulting in operating profitability
Provider: Edison Investment Research Limited
Analyst: ROMANOFF S
Company: Basilea Pharmaceutica AG
Industry: Medical - Biomedical and Genetics
Company: Basilea Pharmaceutica AG
Industry: Medical - Biomedical and Genetics
Company: Basilea Pharmaceutica AG
Industry: Medical - Biomedical and Genetics
Third leg of strategy executed with debt repayment
Provider: Edison Investment Research Limited
Analyst: ROMANOFF S
Company: Basilea Pharmaceutica AG
Industry: Medical - Biomedical and Genetics
Company: Basilea Pharmaceutica AG
Industry: Medical - Biomedical and Genetics
Third oncology asset sale announced, as planned
Provider: Edison Investment Research Limited
Analyst: ROMANOFF S
Company: Basilea Pharmaceutica AG
Industry: Medical - Biomedical and Genetics
Ceftobiprole ERADICATE Trial Data Presented; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Basilea Pharmaceutica AG
Industry: Medical - Biomedical and Genetics
Company: Basilea Pharmaceutica AG
Industry: Medical - Biomedical and Genetics
BAL0891 Licensing Deal Consummated; Raising PT to CHF87
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R